Viewing Study NCT05597995


Ignite Creation Date: 2025-12-24 @ 1:17 PM
Ignite Modification Date: 2025-12-26 @ 9:38 AM
Study NCT ID: NCT05597995
Status: UNKNOWN
Last Update Posted: 2022-10-28
First Post: 2022-10-20
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Treatment of Epidermoid Cysts
Sponsor: Goldman, Butterwick, Fitzpatrick and Groff
Organization:

Study Overview

Official Title: A Prospective Clinical Trial Evaluating the Efficacy of 1.5% Sodium Tetradecyl Sulfate Foam Injection for the Treatment of Epidermoid Cysts
Status: UNKNOWN
Status Verified Date: 2022-10
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The objective of this study is to determine the efficacy, safety, tolerability, and patient satisfaction associated with the treatment of epidermoid cysts with injected 1.5% sodium tetradecyl sulfate (STS) foam.
Detailed Description: The primary objective is to determine the efficacy of STS foam injection on EIC with an endpoint of clinical resolution and cyst wall destruction on histology.

Enrolled subjects will undergo aspiration of cyst contents through an 18g needle immediately followed by injection of 1.5% STS foam (until the cyst is full and foam is flowing out of the injection site) followed by surgical excision 60 days later. The foam will be created by diluting 3% STS with an equal volume of normal saline then mixing with air in a 1:4 ratio using a female-to-female coupler.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: